Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Science immunology - 8(2023), 90 vom: 22. Dez., Seite eabp8966 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciimmunol.abp8966 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343776448 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343776448 | ||
| 003 | DE-627 | ||
| 005 | 20231227140822.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciimmunol.abp8966 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM343776448 | ||
| 035 | |a (NLM)35857576 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bastard, Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Vazquez, Sara E |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jamin |e verfasserin |4 aut | |
| 700 | 1 | |a Laurie, Matthew T |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chung Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Gervais, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Le Voyer, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Bizien, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Zamecnik, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Philippot, Quentin |e verfasserin |4 aut | |
| 700 | 1 | |a Rosain, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Catherinot, Emilie |e verfasserin |4 aut | |
| 700 | 1 | |a Willmore, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Anthea M |e verfasserin |4 aut | |
| 700 | 1 | |a Bair, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Garçon, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Kenney, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Fekkar, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Salagianni, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Poulakou, Garyphallia |e verfasserin |4 aut | |
| 700 | 1 | |a Siouti, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Sahanic, Sabina |e verfasserin |4 aut | |
| 700 | 1 | |a Tancevski, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Günter |e verfasserin |4 aut | |
| 700 | 1 | |a Nagl, Laurenz |e verfasserin |4 aut | |
| 700 | 1 | |a Manry, Jérémy |e verfasserin |4 aut | |
| 700 | 1 | |a Duvlis, Sotirija |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo-Sánchez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Paz Artal, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Perani, Cristiano |e verfasserin |4 aut | |
| 700 | 1 | |a Bezzi, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Sottini, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Quaresima, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Roussel, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Vinh, Donald C |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Luis Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Garzaro, Margaux |e verfasserin |4 aut | |
| 700 | 1 | |a Hatipoglu, Nevin |e verfasserin |4 aut | |
| 700 | 1 | |a Boutboul, David |e verfasserin |4 aut | |
| 700 | 1 | |a Tandjaoui-Lambiotte, Yacine |e verfasserin |4 aut | |
| 700 | 1 | |a Borghesi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Aliberti, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Cassaniti, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Venet, Fabienne |e verfasserin |4 aut | |
| 700 | 1 | |a Monneret, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Halwani, Rabih |e verfasserin |4 aut | |
| 700 | 1 | |a Sharif-Askari, Narjes Saheb |e verfasserin |4 aut | |
| 700 | 1 | |a Danielson, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Burrel, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Morbieu, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Stepanovskyy, Yurii |e verfasserin |4 aut | |
| 700 | 1 | |a Bondarenko, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Volokha, Alla |e verfasserin |4 aut | |
| 700 | 1 | |a Boyarchuk, Oksana |e verfasserin |4 aut | |
| 700 | 1 | |a Gagro, Alenka |e verfasserin |4 aut | |
| 700 | 1 | |a Neuville, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Neven, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a Keles, Sevgi |e verfasserin |4 aut | |
| 700 | 1 | |a Hernu, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Bal, Antonin |e verfasserin |4 aut | |
| 700 | 1 | |a Novelli, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Novelli, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Saker, Kahina |e verfasserin |4 aut | |
| 700 | 1 | |a Ailioaie, Oana |e verfasserin |4 aut | |
| 700 | 1 | |a Antolí, Arnau |e verfasserin |4 aut | |
| 700 | 1 | |a Jeziorski, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Rocamora-Blanch, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Delaunay, Clarisse |e verfasserin |4 aut | |
| 700 | 1 | |a Lhuillier, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Le Turnier, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Mahevas, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Pan-Hammarström, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Abolhassani, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Bompoil, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Dorgham, Karim |e verfasserin |4 aut | |
| 700 | 0 | |a COVID HGE Consortium |e verfasserin |4 aut | |
| 700 | 0 | |a French COVID Study Group |e verfasserin |4 aut | |
| 700 | 0 | |a COMET Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Gorochov, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Laouenan, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Gallego, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Lisa F P |e verfasserin |4 aut | |
| 700 | 1 | |a Renia, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Pujol, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Belot, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Raffi, François |e verfasserin |4 aut | |
| 700 | 1 | |a Allende, Luis M |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Picado, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Ozcelik, Tayfun |e verfasserin |4 aut | |
| 700 | 1 | |a Imberti, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Notarangelo, Luigi D |e verfasserin |4 aut | |
| 700 | 1 | |a Troya, Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Solanich, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shen-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Puel, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Trouillet-Assant, Sophie |e verfasserin |4 aut | |
| 700 | 0 | |a et al |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Science immunology |d 2016 |g 8(2023), 90 vom: 22. Dez., Seite eabp8966 |w (DE-627)NLM263875547 |x 2470-9468 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:90 |g day:22 |g month:12 |g pages:eabp8966 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciimmunol.abp8966 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 90 |b 22 |c 12 |h eabp8966 | ||